• Home
  • Shop
  • About
  • FAQ
  • Contact
  • Compare Peptides
  • Wholesale
  • Prostamax (KEDP) – Research Compound Profile

    Prostamax (KEDP) – Research Compound Profile

    Category: Prostate Research | Molecular Type: Synthetic Tetrapeptide Bioregulator (Lys-Glu-Asp-Pro / KEDP) | Research Status: Preclinical

    This page compiles published research data for qualified researchers. Prostamax (KEDP) is sold exclusively as a research compound and is not approved for human use. No human clinical trials have been published for this peptide.

    Purchase for Research →

    Molecular Overview

    Prostamax is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro (H-Lys-Glu-Asp-Pro-OH), developed through decades of research at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Prof. Vladimir Khavinson [1][2]. The KEDP peptide belongs to the class of ultrashort bioregulatory peptides (USPs) — synthetic compounds of 2–4 amino acid residues designed to mimic endogenous regulatory peptides identified in tissue extracts.

    Khavinson’s bioregulatory peptide program generated tissue-specific tetrapeptides through fractionation and sequencing of organ-derived regulatory factors, with KEDP identified as the prostate-targeted sequence [1]. Prostamax has been investigated in preclinical models for its effects on chromatin structure, gene expression, and inflammatory responses in prostate tissue [3][4]. The compound is classified within the broader family of Khavinson peptides alongside other tissue-specific bioregulators such as Epithalon (pineal), Thymalin (thymus), and Cortexin (brain) [2][12].

    Mechanism of Action

    The proposed mechanism of action for KEDP centers on epigenetic modulation rather than classical receptor-mediated signaling. Unlike traditional receptor-binding peptides (such as GH-releasing peptides that bind to ghrelin receptors), Khavinson bioregulators are hypothesized to penetrate cell membranes and interact directly with chromatin structure at the nuclear level [2][5].

    Cellular Entry and Transport

    Molecular modeling data published by Khavinson et al. (2022) investigated potential cellular entry pathways for KEDP, examining binding affinity to proton-coupled oligopeptide transporters (POT family: PEPT1, PEPT2) and L-type amino acid transporters (LAT1/LAT2) [6]. The study specifically noted that KEDP demonstrates a relatively low binding affinity to the LAT1 transporter (ICM-Score: −13.58, below the high-affinity threshold of −15), suggesting that alternative transport mechanisms — possibly PEPT1/PEPT2-mediated uptake or direct passive membrane penetration — may play a more significant role in KEDP’s cellular entry [6]. The precise mechanism of membrane translocation for KEDP remains an active area of investigation.

    Chromatin Remodeling and Gene Expression

    Once internalized, KEDP is proposed to modulate chromatin architecture through interactions with pericentromeric heterochromatin. In a 2004 study published in Biofizika, Meskhi et al. investigated the effects of KEDP on heterochromatin in aged human lymphocytes in situ [7]. The researchers observed that KEDP induced a redistribution of thermal denaturation profiles — specifically shifting endotherms T(d)III and T(d)IV downward by 2.9 °C and 1.0 °C, respectively [7]. This thermodynamic shift corresponds to a relaxation of condensed 30-nm chromatin fibers into extended 10-nm filaments, effectively reopening genomic regions that had been silenced by age-related heterochromatinization [5][7].

    Complementary findings from the same study showed that KEDP treatment increased the frequency of sister chromatid exchanges and elevated Ag-positive nucleolus organizer regions, both indicators of enhanced chromosomal activity and ribosomal RNA gene function [7]. In a related 2004 study published in Bulletin of Experimental Biology and Medicine, Khavinson et al. observed similar chromatin decondensation effects in lymphocytes from senile subjects treated with short peptides, supporting the broader hypothesis of peptide-mediated epigenetic regulation [5].

    A 2021 systematic review by Khavinson et al. in Molecules compiled evidence for the gene-regulatory properties of ultrashort peptides, describing the proposed framework by which di-, tri-, and tetrapeptides interact with histone proteins and DNA to influence transcription of genes involved in cellular repair, protein synthesis, and anti-inflammatory signaling [2].

    Structural Determinants of Activity

    KEDP’s four-residue sequence (Lys-Glu-Asp-Pro) combines a basic lysine residue, two acidic residues (Glu, Asp), and a C-terminal proline. This charge arrangement — a net-neutral peptide with spatially separated basic and acidic side chains — has been proposed as relevant to the peptide’s reported affinity for negatively charged DNA phosphate backbones and for histone tail sequences enriched in basic residues [2][5]. The C-terminal proline, lacking an amide hydrogen on its backbone nitrogen, constrains the peptide’s conformational flexibility relative to peptides composed entirely of standard residues, a structural feature shared with other tissue-specific Khavinson tetrapeptides that terminate in proline or glycine [2].

    Tissue-Specific Activity

    In organotypic tissue culture experiments, Zakutskii et al. (2006) demonstrated tissue-specific effects of synthetic peptide bioregulators in young and old rat tissues, providing evidence that KEDP and related peptides exhibit preferential activity in their target organ systems [1].

    Published Research Parameters

    The following table indexes study models, durations, and reported observations from peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

    Study / YearModelDurationKey ObservationReference
    Borovskaya et al., 2013Rat (chronic aseptic prostatitis model)15 daysReduced prostate swelling, hyperemia, and lymphoid infiltration[3]
    Borovskaya et al., 2014Wistar rat (sulpiride-induced BPH model)60 daysStatistically significant decrease in prostate mass and prostate volume relative to untreated controls[4]
    Khavinson et al., 2004Aged human lymphocytes (in vitro)In vitroChromatin decondensation; measurable thermal shift in endotherms[5]
    Meskhi et al., 2004Human lymphocytes (in situ)In situIncreased sister chromatid exchanges; elevated Ag-positive NOR regions[7]
    Khavinson et al., 2022In silico (molecular modeling)N/ALow predicted binding affinity to the LAT1 transporter[6]
    Zakutskii et al., 2006Organotypic tissue culture (young/old rats)In vitroTissue-specific effects of synthetic peptide bioregulators demonstrated[1]
    Sinjari et al., 2020Oral stem cells (in vitro)In vitroShort peptides protected oral stem cells from aging[14]

    Analytical Characterization

    As a four-residue synthetic peptide (H-Lys-Glu-Asp-Pro-OH), KEDP presents characterization considerations shared with other Khavinson-class ultrashort peptides. RP-HPLC with UV detection resolves the intact tetrapeptide from truncated or deletion-sequence byproducts of solid-phase synthesis, and retention behavior is sensitive to the acidic glutamate and aspartate side chains, requiring pH-controlled mobile phases for reproducible separation. ESI-MS or MALDI-TOF confirms the intact monoisotopic mass and can detect common short-peptide degradation products, including deamidation at the internal Glu/Asp residues and cyclization involving the C-terminal proline, a residue known to promote diketopiperazine formation in short peptide sequences under certain storage conditions. Because the proline residue introduces conformational rigidity at the C-terminus, chiral-purity assessment (e.g., chiral-phase HPLC) is relevant to confirm retention of the native L-configuration at each stereocenter, since racemization during synthesis or storage would alter the peptide’s chromatin-binding behavior. Amino acid analysis provides an independent, sequence-based quantitation of peptide content that is not confounded by residual counter-ion, buffer salts, or moisture contributing to gross lyophilizate mass.

    Stability & Storage Characteristics

    Published data and manufacturer specifications indicate the following stability characteristics for lyophilized tetrapeptide bioregulators:

    • Lyophilized stability: Sealed lyophilized vials stored at −20 °C (−4 °F) have been reported to maintain peptide integrity for 24+ months [10]. Short-term storage at 2–8 °C (35.6–46.4 °F) in a dry, light-protected environment is considered acceptable for durations up to approximately 6 months [10].
    • Light sensitivity: As with most peptide compounds, storage away from direct light is recommended to minimize photodegradation [10].

    Key Published Research Findings

    The following findings are derived from published peer-reviewed literature. Each observation is attributed to its source study.

    • Reduced inflammatory markers in a rat prostate tissue model: In a 2013 study published in Modern Research in Inflammation, Borovskaya et al. reported that KEDP administration in a rat model of localized prostate tissue inflammation was associated with reduced prostate swelling, vascular congestion (hyperemia), and lymphoid infiltration, along with fewer sclerotic and atrophic tissue changes relative to untreated control animals [3].

    • Reduced prostate mass and volume in a rodent tissue-remodeling model: In a 2014 study published in Modern Research in Inflammation, Borovskaya et al. investigated KEDP in a sulpiride-induced prostate tissue enlargement model in Wistar rats over a 60-day study period. The study documented a statistically significant decrease in prostate mass, weight coefficient, and prostate volume relative to untreated controls [4].

    • Reduced glandular epithelial proliferation markers: In the same 2014 study, the area of glandular acinar epithelium — a histological marker of tissue proliferation — was significantly reduced relative to controls, and the pattern of inflammatory cell infiltration shifted from diffuse to localized, indicating a measurable anti-inflammatory effect [4].

    • Chromatin remodeling in aged lymphocytes: In a 2004 study published in Bulletin of Experimental Biology and Medicine, Khavinson et al. demonstrated that KEDP and related short peptides induced decondensation of pericentromeric heterochromatin in lymphocytes from senile subjects, with thermal shifts of 2.9 °C and 1.0 °C for key endotherms — a molecular signature associated with restored gene accessibility [5]. Meskhi et al. (2004) published complementary findings in Biofizika, reporting increased sister chromatid exchanges and elevated Ag-positive nucleolus organizer regions in KEDP-treated human lymphocytes [7].

    • Peptide regulation of gene expression: A 2021 systematic review by Khavinson et al. in Molecules compiled evidence across the Khavinson bioregulatory peptide family, describing mechanisms by which ultrashort peptides — including KEDP — are proposed to influence gene expression through direct chromatin interactions [2]. Khavinson et al. (2017) additionally reported on peptide epigenetic regulators in the context of lifespan variation across rodent species [12].

    • Cellular protection in aging models: Sinjari et al. (2020) demonstrated in Stem Cell Reviews and Reports that short peptides from the Khavinson bioregulatory class protected oral stem cells from aging-related decline in vitro, contributing to the broader evidence base for the cytoprotective properties of this peptide family [14].

    Regulatory Status

    • FDA approval: Prostamax (KEDP) has not been approved by the U.S. Food and Drug Administration for any indication.
    • Clinical trial status: No human clinical trials for Prostamax (KEDP) are currently registered on ClinicalTrials.gov. All published research to date has been conducted in preclinical animal models or in vitro/in situ cell systems.
    • Research compound classification: Prostamax is sold exclusively as a research compound for investigational laboratory use. It is not intended for human consumption, therapeutic application, or diagnostic use.
    • Applicable regulations: All research involving Prostamax must comply with applicable federal, state, and institutional regulations governing research compounds and laboratory safety.

    References

    1. Advances in Gerontology (2006) — Zakutskii AN, Chalisova NI, Ryzhak GA, et al. “The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats.” Adv Gerontol. 19:93-96. PMID: 17152728. View Source

    2. Molecules (2021) — Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. “Peptide Regulation of Gene Expression: A Systematic Review.” Molecules. 26(22):7053. doi: 10.3390/molecules26227053. View Source

    3. Modern Research in Inflammation (2013) — Borovskaya TG, Pakhomova AV, Vychuzhanina AV, et al. “Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications.” Mod Res Inflamm. 2:54-58. doi: 10.4236/mri.2013.23007. View Source

    4. Modern Research in Inflammation (2014) — Borovskaya TG, Fomina TI, Shchemerova JA, et al. “Experimental Study of Efficiency of Tetrapeptide Lysil-Glutamyl-Aspartyl-Proline Using the Model of Benign Prostatic Hyperplasia.” Mod Res Inflamm. 3(3):108-112. doi: 10.4236/mri.2014.33013. View Source

    5. Bulletin of Experimental Biology and Medicine (2004) — Khavinson VKh, Lezhava TA, Malinin VV. “Effects of short peptides on lymphocyte chromatin in senile subjects.” Bull Exp Biol Med. 137(1):78-81. doi: 10.1023/B:BEBM.0000024393.40560.05. PMID: 15085253. View Source

    6. International Journal of Molecular Sciences (2022) — Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. “Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.” Int J Mol Sci. 23(14):7733. doi: 10.3390/ijms23147733. View Source

    7. Biofizika (2004) — Meskhi T, Khachidze D, Barbakadze Sh, et al. “The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ.” Biofizika. 49(6):1091-1093. PMID: 15612551. View Source

    8. NIBSC / MHRA — “Peptide Handling, Dissolution, and Storage Best Practices.” National Institute for Biological Standards and Control. View Source

    9. Bulletin of Experimental Biology and Medicine (2017) — Khavinson VK, Kormilets DY, Mar’yanovich AT. “Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan.” Bull Exp Biol Med. 163(5):671-676. doi: 10.1007/s10517-017-3876-x. PMID: 28948547. View Source

    10. Bulletin of Experimental Biology and Medicine (2013) — Borovskaya TG, Fomina TI, Ermolaeva LA, et al. “Comparative Evaluation of the Efficiency of Prostatotropic Agents of Natural Origin in Experimental Benign Prostatic Hyperplasia.” Bull Exp Biol Med. 155:73-77. doi: 10.1007/s10517-013-2081-9. PMID: 23667874. View Source

    11. Stem Cell Reviews and Reports (2020) — Sinjari B, Diomede F, Khavinson V, et al. “Short Peptides Protect Oral Stem Cells from Ageing.” Stem Cell Rev Rep. 16:159-166. doi: 10.1007/s12015-019-09921-3. PMID: 31677028. View Source

    12. Neuroepigenetic Mechanisms of Ultrashort Peptides (2022) — Khavinson V, Linkova N, et al. “Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease.” Int J Mol Sci. PMC9032300. View Source

    13. Advances in Gerontology (2014) — Khavinson VK, Tarnovskaia SI, Lin’kova NS, et al. “Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging.” Adv Gerontol. 27:108-114. PMID: 25051766. View Source


    ⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Prostamax (KEDP) is sold exclusively as a research compound and has not been approved by the FDA for human consumption. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

    Purchase Prostamax (KEDP) for Research →